Alzheimer's Association Statement on Oral Semaglutide Phase 3 Topline Data Release
- Written by PR Newswire
![]() |
- Results Underscore Need for Continued Research and Diverse Treatment Pipeline
CHICAGO, Nov. 24, 2025 /PRNewswire/ -- The Alzheimer's Association is disappointed that the evoke and evoke+ clinical trials did not demonstrate a statistically significant reduction in Alzheimer's disease progression. The studies tested an oral semaglutide pill...
Read more: Alzheimer's Association Statement on Oral Semaglutide Phase 3 Topline Data Release















